NCT04721366View on ClinicalTrials.gov

A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease

CompletedOBSERVATIONAL
Enrollment

11

Participants

Timeline

Start Date

January 8, 2021

Primary Completion Date

April 17, 2023

Study Completion Date

April 17, 2023

Conditions
Gaucher Disease
Interventions
OTHER

Standard of Care

Neonatal and pediatric participants who has been on ERT (VPRIV) will be assessed as per SOC.

Trial Locations (1)

22030

Lysosomal & Rare Disorders Research & Treatment Center, Fairfax

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY